Schedule 13D Filing by Northstrive Fund II LP and Braeden Lichti Regarding Bluejay Diagnostics, Inc.

Northstrive Fund II LP and Braeden Lichti, the Reporting Persons, have filed a Schedule 13D, amending a previous Schedule 13G, concerning the Common Stock of Bluejay Diagnostics, Inc. The filing discloses that as of March 10, 2026, Northstrive Fund beneficially owned 11,000 shares (1.13%) and Mr. Lichti beneficially owned 35,500 shares (3.65%) of the Issuer's outstanding Common Stock. This Schedule 13D is being filed to report on a letter sent by Northstrive Fund to the Issuer's Board of Directors on March 11, 2026. The letter recommends that the Board review a potential biotechnology acquisition opportunity identified by Northstrive Fund, which they believe could strengthen the Issuer's clinical pipeline and enhance shareholder value. The Reporting Persons intend to continuously review their investment and may take future actions, including liquidation or further accumulation of shares. They have also deemed it appropriate to file this Schedule 13D due to the potential change or influence of control indicated by the Board Letter.